|
Q1 FY2027
As of Sep 30, 2026
|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash and due from banks | ||||||||||||||
| Interest-bearing deposits at other banks | ||||||||||||||
| Federal funds sold | ||||||||||||||
| Total cash and cash equivalents | ||||||||||||||
| Securities available-for-sale, at fair value | ||||||||||||||
| Securities held-to-maturity, at amortized cost | ||||||||||||||
| Equity securities, at fair value | ||||||||||||||
| Loans receivable, net of allowance for credit losses of $5,076 and $1,116, respectively | ||||||||||||||
| Loans receivable, net of allowance for credit losses of $5,533 and $5,582, respectively | ||||||||||||||
| Loans receivable, net of allowance for credit losses of $6,116 and $5,938, respectively | ||||||||||||||
| Premises and equipment, net | ||||||||||||||
| Right-of-use asset | ||||||||||||||
| Restricted equity securities, at cost | ||||||||||||||
| Accrued interest receivable | ||||||||||||||
| Bank owned life insurance | ||||||||||||||
| Goodwill and intangible assets | ||||||||||||||
| Other assets | ||||||||||||||
| Total assets | ||||||||||||||
| Liabilities | ||||||||||||||
| Noninterest-bearing | ||||||||||||||
| Interest-bearing | ||||||||||||||
| Total deposits | ||||||||||||||
| Borrowings | ||||||||||||||
| Advance payments by borrowers for taxes and insurance | ||||||||||||||
| Accrued interest payable | ||||||||||||||
| Lease liability | ||||||||||||||
| Other liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| Equity | ||||||||||||||
| Preferred Stock, $0.01 par value, 5,000,000 shares authorized, none issued | ||||||||||||||
| Common stock, $0.01 par value, 50,000,000 authorized; 7,917,229 and 7,934,356 shares issued and outstanding as of September 30, 2026, and June 30, 2026, respectively | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Unearned compensation ESOP | ||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||
| Total stockholders' equity | ||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||
Loading...